This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Has Avnet (AVT) Outpaced Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (AVT) Outperforming Other Computer and Technology Stocks This Year?
Avnet (AVT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Avnet (AVT) closed at $43.12, marking a +0.33% move from the previous day.
Why Avnet (AVT) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Avnet (AVT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Avnet (AVT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Avnet (AVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Avnet (AVT) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Avnet (AVT) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Avnet (AVT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Avnet (AVT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Avnet (AVT) closed at $41.12, marking a +1.76% move from the previous day.
Avnet (AVT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Avnet (AVT) closed at $40.39, marking a -0.35% move from the previous day.
Avnet (AVT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Avnet (AVT) closed at $40.23, marking a -0.72% move from the previous day.
Avnet (AVT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Avnet (AVT) closed at $39.26 in the latest trading session, marking a +0.67% move from the prior day.
Avnet (AVT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Avnet (AVT) closed at $38.79 in the latest trading session, marking a -1.65% move from the prior day.
Avnet (AVT) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Avnet's (AVT) second-quarter fiscal 2021 top-line results reflect stellar growth across Asia, which more than offset the negative impact of soft sales across the Americas and EMEA regions.
Avnet (AVT) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Avnet (AVT) delivered earnings and revenue surprises of 26.32% and 10.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Xilinx (XLNX) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Though Xilinx's (XLNX) Q3 performance is likely to have gained from solid demand for cloud-based storage and services, the Huawei ban and other trade-related uncertainties might have been deterrents.
F5 Networks (FFIV) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Increased IT spending resulting from the remote-working and online-learning wave amid the COVID-19 pandemic is likely to have aided F5 Networks' (FFIV) Q1 performance.
What's in the Offing for CACI International (CACI) Q2 Earnings?
by Zacks Equity Research
CACI International's (CACI) second-quarter fiscal 2021 results are likely to reflect organic revenue growth and continued margin expansion.
Citrix (CTXS) Q4 Earnings Decline Y/Y, Announces Wrike Buyout
by Zacks Equity Research
Citrix's (CTXS) Q4 performance is supported by solid momentum in workspace and desktop virtualization solutions. The company also announced the buyout of Wrike for $2.25 billion.
Seagate (STX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Seagate's (STX) second-quarter fiscal 2021 performance is likely to benefit from increasing clout of mass capacity storage solutions and gradual recovery in the video and image applications' market.
Is Avnet (AVT) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Progress Software (PRGS) Q4 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Progress Software (PRGS) fourth-quarter 2020 results reflect strong sales of OpenEdge and DCI products.
Logitech (LOGI) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Though a solid Video Collaboration business is anticipated to have aided Logitech's (LOGI) third-quarter fiscal 2021 performance, a weak Mobile Speakers segment might have been an overhang.
Infosys (INFY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While Infosys' (INFY) Q3 performance is likely to have benefited from the ongoing digital transformations and large deal wins, elevated expenses might have hurt the bottom line.
F5 Networks (FFIV) to Acquire Volterra to Build Edge Platform
by Zacks Equity Research
F5 Networks (FFIV) enters into an agreement to acquire Volterra, to create a new Edge 2.0 platform for enterprises and service providers, in collaboration with the latter's technology platform.
SYNNEX (SNX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
SYNNEX's (SNX) Q4 earnings might have been affected by the slowdown in technology spending by enterprises and supply-chain disruptions due to the COVID-19 pandemic.
Simulations Plus (SLP) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Simulations Plus (SLP) fiscal first-quarter results are likely to reflect gains from solid uptick in modeling and simulations workflow platform for drug development across pharma and biotech industries.